Targets › HTR4
7 programs from 7 companies in 10 trials: 5 Phase 3, 2 Phase 2, 2 Phase 4, 1 Phase 1; Other, Gastroenterology, Infectious disease; next expected readout Dec 2026.
G protein-coupled receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone and a mitogen. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors. (UniProt, Q13639)
Open in Phaseline: the race on HTR4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sanliurfa Education and Research Hospital | metoclopramide Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist | DRD2, HTR3A, HTR4 | Phase 4 | Intraoperative Nausea-retching-vomiting Episodes | Jan 2027 |
| Boston Children's Hospital | Prucalopride Serotonin 4 (5-HT4) receptor agonist | HTR4 | Phase 4 | Esophageal Motility Disorders | May 2027 |
| Valenta Pharm JSC | 4-MUST (trimebutine 4-methylumbelliferyl sulfate) Trimebutine derivative; prokinetic agent acting as TRPV1 agonist and 5-HT4 receptor agonis | TRPV1, HTR4 | Phase 3 | Chronic Cholecystitis | Dec 2026 |
| Affiliated Hospital of Qinghai University | Metoclopramide Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist | DRD2, HTR3A, HTR4 | Phase 3 | Nausea | Dec 2027 |
| Tanta University | Itopride 5-HT4 receptor partial agonist and dopamine antagonist | HTR4 | Phase 3 | Spontaneous Bacterial Peritonitis | Dec 2028 |
| Future University in Egypt | Prucalopride Serotonin 4 (5-HT4) receptor agonist | HTR4 | Phase 3 | Post-Op Complication | – |
| Simon Fisher | Metoclopramide Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist | DRD2, HTR3A, HTR4 | Phase 2 | Hypoglycemia Unawareness | Jun 2027 |
Chronic Cholecystitis (3) Post-Op Complication (2) Nausea (1) Intraoperative Nausea-retching-vomiting Episodes (1) Spontaneous Bacterial Peritonitis (1) Hypoglycemia Unawareness (1) Esophageal Motility Disorders (1)
small molecule (7)
Future University in Egypt (1) Valenta Pharm JSC (1) Affiliated Hospital of Qinghai University (1) Sanliurfa Education and Research Hospital (1) Tanta University (1) Simon Fisher (1) Boston Children's Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.